AU2022239051A1 - Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis - Google Patents

Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis Download PDF

Info

Publication number
AU2022239051A1
AU2022239051A1 AU2022239051A AU2022239051A AU2022239051A1 AU 2022239051 A1 AU2022239051 A1 AU 2022239051A1 AU 2022239051 A AU2022239051 A AU 2022239051A AU 2022239051 A AU2022239051 A AU 2022239051A AU 2022239051 A1 AU2022239051 A1 AU 2022239051A1
Authority
AU
Australia
Prior art keywords
chain variable
variable region
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022239051A
Other languages
English (en)
Other versions
AU2022239051A9 (en
Inventor
Isaac Cann
Corina Gabazza
Esteban GABAZZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mie University
University of Illinois System
Original Assignee
Mie University
University of Illinois at Urbana-Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mie University, University of Illinois at Urbana-Champaign, University of Illinois System filed Critical Mie University
Publication of AU2022239051A1 publication Critical patent/AU2022239051A1/en
Publication of AU2022239051A9 publication Critical patent/AU2022239051A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022239051A 2021-03-19 2022-03-18 Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis Pending AU2022239051A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021046301 2021-03-19
JP2021-046301 2021-03-19
JP2021173381 2021-10-22
JP2021-173381 2021-10-22
PCT/JP2022/012823 WO2022196816A1 (ja) 2021-03-19 2022-03-18 急性肺障害および肺線維症の急性増悪を改善するための医薬組成物

Publications (2)

Publication Number Publication Date
AU2022239051A1 true AU2022239051A1 (en) 2023-10-12
AU2022239051A9 AU2022239051A9 (en) 2023-10-26

Family

ID=83320552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022239051A Pending AU2022239051A1 (en) 2021-03-19 2022-03-18 Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis

Country Status (8)

Country Link
US (1) US20260116957A1 (cg-RX-API-DMAC7.html)
EP (1) EP4310099A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022196816A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230171941A (cg-RX-API-DMAC7.html)
AU (1) AU2022239051A1 (cg-RX-API-DMAC7.html)
CA (1) CA3214262A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023010992A (cg-RX-API-DMAC7.html)
WO (1) WO2022196816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116570716B (zh) * 2023-04-28 2025-05-16 水木星辰生物制药(深圳)有限公司 lncRNA LOC646762表达的抑制剂的应用和药物
CN117327147B (zh) * 2023-09-26 2024-05-10 广东海洋大学 一种抗急性肺损伤多肽及其应用
WO2026134246A1 (ja) * 2024-12-18 2026-06-25 国立大学法人三重大学 Corisin発現非ヒト動物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
JP6394441B2 (ja) * 2014-04-07 2018-09-26 株式会社デンソー 内燃機関の冷却装置
US10280223B2 (en) * 2014-07-09 2019-05-07 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
EP3380521A1 (en) * 2015-11-24 2018-10-03 Eli Lilly and Company Combination therapy for cancer
WO2017214456A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3678717B1 (en) * 2017-09-04 2026-07-08 Wockhardt Limited Autoinjector with a needle cover
EP3629024A1 (en) * 2018-09-26 2020-04-01 Assistance Publique - Hôpitaux de Marseille Cd146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosis
EP3689373A1 (en) * 2019-01-30 2020-08-05 IDT Biologika GmbH Inactivated apxia, apxiia and apxiiia toxins
JP2021046301A (ja) 2019-09-19 2021-03-25 株式会社Screenホールディングス フィルムの剥離装置及び、フィルムの剥離方法
US11723926B2 (en) * 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US20230357373A1 (en) * 2019-12-17 2023-11-09 Mie University Methods and compositions for evaluating and treating fibrosis
JP2021173381A (ja) 2020-04-28 2021-11-01 トヨタ自動車株式会社 ファンカップリング装置の制御装置

Also Published As

Publication number Publication date
US20260116957A1 (en) 2026-04-30
EP4310099A1 (en) 2024-01-24
JPWO2022196816A1 (cg-RX-API-DMAC7.html) 2022-09-22
AU2022239051A9 (en) 2023-10-26
MX2023010992A (es) 2023-11-14
WO2022196816A1 (ja) 2022-09-22
KR20230171941A (ko) 2023-12-21
CA3214262A1 (en) 2022-09-22
EP4310099A4 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
US20260116957A1 (en) Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis
DK3054298T3 (en) METHOD OF DETECTING TUMOR IN THE ARC
AU2022202256A1 (en) N-terminal epitopes in Amyloid beta and conformationally-selective antibodies thereto
EP2248826B1 (en) Antibody directed against pcrv
AU2014336111A1 (en) Cross-reactive Staphylococcus aureus antibody sequences
CN117106080B (zh) 人源抗鼠疫耶尔森菌LcrV的抗体及其相关产品和用途
US20180298084A1 (en) Bactericidal monoclonal antibody targeting klebsiella pneumoniae
KR20180083869A (ko) 케이. 뉴모니애 (K. pneumoniae)의 만난-기반 O-항원을 표적화 하는 항체
US11485776B2 (en) Antibodies against infectious diseases
JP2022520723A (ja) さまざまな真菌病原体に関連する感染症および疾患の治療および検出
CN117425672A (zh) 用于改善急性肺损伤和肺纤维化急性加重的药物组合物
US9868784B2 (en) Antibodies against the S100P protein for the treatment and diagnosis of cancer
JP7750490B2 (ja) 線維症の評価および処置のための方法および組成物
US20190161534A1 (en) Anti-galactan ii monoclonal antibodies targeting klebsiella pneumoniae
JP5925783B2 (ja) アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物
EP3497124A1 (en) Klebsiella pneumoniae o3 specific antibodies
WO2023156186A1 (en) Markers for high-affinity sars-cov-2 spike protein antibodies
KR101565443B1 (ko) hnRNP-A2/B1를 포함하는 베체트병 진단용 키트
Cann et al. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis

Legal Events

Date Code Title Description
SREP Specification republished